Meyka Pro banner
SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited Fundamental Analysis (JPX: 4582.T)

4582.T●JPX
HealthcareMedical - Pharmaceuticals
¥69.00
¥9.00(11.54%)
Japanese Market opens in NaNh NaNm

SymBio Pharmaceuticals Limited Fundamental Analysis (JPX: 4582.T)

SymBio Pharmaceuticals Limited (JPX: 4582.T) shows moderate financial fundamentals with a PE ratio of -0.76, profit margin of -5.75%, and ROE of 65.00%. The company generates $0.7B in annual revenue with weak year-over-year growth of -46.69%.

Key Strengths

ROE65.00%
PEG Ratio-0.23

Areas of Concern

Operating Margin-5.64%
Cash Position4.38%
Current Ratio0.40
We analyze 4582.T's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -429.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-429.9/100

We analyze 4582.T's fundamental strength across five key dimensions:

Efficiency Score

Weak

4582.T struggles to generate sufficient returns from assets.

ROA > 10%
-6.53%

Valuation Score

Excellent

4582.T trades at attractive valuation levels.

PE < 25
-0.76
PEG Ratio < 2
-0.23

Growth Score

Weak

4582.T faces weak or negative growth trends.

Revenue Growth > 5%
-46.69%
EPS Growth > 10%
-11.91%

Financial Health Score

Moderate

4582.T shows balanced financial health with some risks.

Debt/Equity < 1
-0.62
Current Ratio > 1
0.40

Profitability Score

Weak

4582.T struggles to sustain strong margins.

ROE > 15%
65.00%
Net Margin ≥ 15%
-5.75%
Positive Free Cash Flow
No

Key Financial Metrics

Is 4582.T Expensive or Cheap?

P/E Ratio

4582.T trades at -0.76 times earnings. This suggests potential undervaluation.

-0.76

PEG Ratio

When adjusting for growth, 4582.T's PEG of -0.23 indicates potential undervaluation.

-0.23

Price to Book

The market values SymBio Pharmaceuticals Limited at -4.47 times its book value. This may indicate undervaluation.

-4.47

EV/EBITDA

Enterprise value stands at -0.54 times EBITDA. This is generally considered low.

-0.54

How Well Does 4582.T Make Money?

Net Profit Margin

For every $100 in sales, SymBio Pharmaceuticals Limited keeps $-5.75 as profit after all expenses.

-5.75%

Operating Margin

Core operations generate -5.64 in profit for every $100 in revenue, before interest and taxes.

-5.64%

ROE

Management delivers $65.00 in profit for every $100 of shareholder equity.

65.00%

ROA

SymBio Pharmaceuticals Limited generates $-6.53 in profit for every $100 in assets, demonstrating efficient asset deployment.

-6.53%

Following the Money - Real Cash Generation

Operating Cash Flow

SymBio Pharmaceuticals Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.

$0.00

Free Cash Flow

SymBio Pharmaceuticals Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.

$0.00

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

FCF Yield

4582.T converts 0.00% of its market value into free cash.

0.00%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.76

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.23

vs 25 benchmark

P/B Ratio

Price to book value ratio

-4.47

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.59

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.62

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.40

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

65.00

vs 25 benchmark

ROA

Return on assets percentage

-6.53

vs 25 benchmark

ROCE

Return on capital employed

4.63

vs 25 benchmark

How 4582.T Stacks Against Its Sector Peers

Metric4582.T ValueSector AveragePerformance
P/E Ratio-0.7630.24 Better (Cheaper)
ROE6499.80%540.00% Excellent
Net Margin-575.15%-2322.00% (disorted) Weak
Debt/Equity-0.620.08 Strong (Low Leverage)
Current Ratio0.405.59 Weak Liquidity
ROA-653.24%-17516.00% (disorted) Weak

4582.T outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROE, but lagging in Net Margin.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews SymBio Pharmaceuticals Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-71.27%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

23.37%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

27.16%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ